MindWalk (HYFT) Stock: Buy, Sell, or Hold?
HYFT - MindWalk Holdings Corp. Common Stock
$1.16
0.01 (0.87%)
▲
5d:
-10.08%
30d:
-13.43%
90d:
-10.77%
WAIT
LOW Confidence
Analysis Updated: Oct 27, 2026 12:00 AM ET
Earnings: Dec 21, 2026
Get Alerted When HYFT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: HYFT is down 10.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: HYFT is down 10.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: HYFT is currently trading at $1.16, which is considered oversold relative to its 30-day fair value range of $1.25 to $1.47. From a valuation perspective, the stock is trading at a discount (Forward PE: -6.2) compared to its historical average (85.2). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, HYFT is in a downtrend. Immediate support is located at $1.10, while resistance sits at $1.47.
Market Sentiment: HYFT scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $4.33 (+273.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HYFT is in a downtrend. Immediate support is located at $1.10, while resistance sits at $1.47.
Market Sentiment: HYFT scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $4.33 (+273.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.25 -
$1.47
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
95.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 273.6% below Wall St target ($4.33)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- BULLISH: Bottoming setup score 60/100 — corrected, stabilizing, and turning up
- WARNING: Recommendation downgraded due to -10.1% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.25 -
$1.47
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.10
Resistance Level
$1.47
Current Trend
Downtrend
Technical data as of
Oct 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.22
Wall Street Target
$4.33
(+273.6%)
Revenue Growth (YoY)
21.3%
Profit Margin
-105.2%
PE vs Historical
-6.2 vs 85.2
CHEAP
Share & Embed Analysis
Last updated: October 28, 2026 1:43 AM ET
Data refreshes hourly during market hours. Next update: 2:43 AM
Data refreshes hourly during market hours. Next update: 2:43 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HYFT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$196 | 68 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
23 analysts |
$109 | 62 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$685 | 59 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
23 analysts |
$86 | 68 BUY |
|
IMNM
Immunome Inc |
STRONG BUY
17 analysts |
$35 | 56 HOLD |